Growth Metrics

Novartis Ag (NVS) Cash from Financing Activities (2016 - 2025)

Novartis Ag's Cash from Financing Activities history spans 14 years, with the latest figure at -$5.2 billion for Q2 2025.

  • On a quarterly basis, Cash from Financing Activities fell 62.91% to -$5.2 billion in Q2 2025 year-over-year; TTM through Jun 2025 was -$17.2 billion, a 209.84% decrease, with the full-year FY2025 number at -$14.9 billion, down 26.61% from a year prior.
  • Cash from Financing Activities hit -$5.2 billion in Q2 2025 for Novartis Ag, up from -$8.4 billion in the prior quarter.
  • Over the last five years, Cash from Financing Activities for NVS hit a ceiling of $11.1 billion in Q3 2021 and a floor of -$11.8 billion in Q4 2022.
  • Historically, Cash from Financing Activities has averaged -$2.8 billion across 5 years, with a median of -$2.6 billion in 2021.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 485.47% in 2021 and later crashed 1277.92% in 2024.
  • Tracing NVS's Cash from Financing Activities over 5 years: stood at -$11.5 billion in 2021, then dropped by 3.06% to -$11.8 billion in 2022, then skyrocketed by 94.87% to -$607.0 million in 2023, then crashed by 1277.92% to -$8.4 billion in 2024, then skyrocketed by 37.67% to -$5.2 billion in 2025.
  • Business Quant data shows Cash from Financing Activities for NVS at -$5.2 billion in Q2 2025, -$8.4 billion in Q4 2024, and -$382.0 million in Q3 2024.